Investment
Features
FeesSafety
Academy
More
Pluang+

Cogent CEO to present at three major tech and media conferences in early September 2026

Market News
01 Sep 2026
PRNewsWire
View Source
Neutral
pluang ai news

Cogent Communications Holdings, a leading global Internet service provider, announced that CEO Dave Schaeffer will present at three key industry conferences in September 2026: Goldman Sachs Communacopia + Technology Conference, Citi Global TMT Conference, and BofA Securities Media, Communications & Entertainment Conference. These presentations will provide insights into Cogent's business and future plans, accessible via live webcasts on Cogent's website. This engagement highlights Cogent's active role in the tech and communications sectors and offers investors a chance to hear directly from leadership about company strategy and market outlook.

More News

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic beats Q3 earnings and revenue estimates, boosts outlook with $700M investment in Heart Tech and Robotics.

Medtronic reported Q3 earnings per share of $1.45, surpassing estimates of $1.39, and revenue of $9.76 billion, above the $9.55 billion consensus. The strong financial results reflect broad demand for its cardiovascular devices. The company raised it...

Company Fundamentals
Bullish
1 hour ago
Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies set for record Q2 earnings driven by AI server demand and strong revenue growth.

Dell Technologies is expected to report record second-quarter earnings with EPS around $4.91 and revenue near $44.89 billion, fueled by high demand for its AI-optimized servers. This would mark a significant increase from last year's $29.78 billion a...

Company Fundamentals
Bullish
1 hour ago
Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics' price target raised to $180 after FDA approves new drug MIMRYLO.

Protagonist Therapeutics saw its stock price target raised to $180 by Barclays following the FDA approval of MIMRYLO, a first-in-class drug for polycythemia vera. The approval was based on strong Phase 3 trial results with 76.9% patient response, tri...

Analyst Insights
Bullish
2 hours ago
SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

SAIC raises price target after beating Q2 earnings and boosting 2027 outlook

Science Applications International Corporation (SAIC) saw its price target raised to $154 after reporting Q2 earnings of $3.01 per share, surpassing estimates by over 33%, and revenues of $1.88 billion, beating expectations by 7.52%. The company also...

Analyst Insights
Bullish
3 hours ago
Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

Hercules Capital upgraded to Buy by UBS, highlighting strong financials and 11.1% dividend yield.

UBS upgraded Hercules Capital's rating from Neutral to Buy, reflecting confidence in the company's strong financial stability and growth prospects. Hercules Capital, a specialty finance firm supporting tech and life sciences startups, boasts a BBB+ c...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App